123 related articles for article (PubMed ID: 21081028)
1. Genetic variations in androgen metabolism genes and associations with prostate cancer in South African men.
Fernandez P; De Beer PM; Van der Merwe L; Heyns CF
S Afr Med J; 2010 Nov; 100(11):741-5. PubMed ID: 21081028
[TBL] [Abstract][Full Text] [Related]
2. Genetic contribution to variable human CYP3A-mediated metabolism.
Lamba JK; Lin YS; Schuetz EG; Thummel KE
Adv Drug Deliv Rev; 2002 Nov; 54(10):1271-94. PubMed ID: 12406645
[TBL] [Abstract][Full Text] [Related]
3. Association between cytochrome CYP17A1, CYP3A4, and CYP3A43 polymorphisms and prostate cancer risk and aggressiveness in a Korean study population.
Han JH; Lee YS; Kim HJ; Lee SY; Myung SC
Asian J Androl; 2015; 17(2):285-91. PubMed ID: 25337833
[TBL] [Abstract][Full Text] [Related]
4. Genetic variants in CYP (-1A2, -2C9, -2C19, -3A4 and -3A5), VKORC1 and ABCB1 genes in a black South African population: a window into diversity.
Dandara C; Lombard Z; Du Plooy I; McLellan T; Norris SA; Ramsay M
Pharmacogenomics; 2011 Dec; 12(12):1663-70. PubMed ID: 22118051
[TBL] [Abstract][Full Text] [Related]
5. High predictive value of CYP2B6 SNPs for steady-state plasma efavirenz levels in South African HIV/AIDS patients.
Swart M; Skelton M; Ren Y; Smith P; Takuva S; Dandara C
Pharmacogenet Genomics; 2013 Aug; 23(8):415-27. PubMed ID: 23778320
[TBL] [Abstract][Full Text] [Related]
6. Impact of a genetic variant in CYP3A4 on risk and clinical presentation of prostate cancer among white and African-American men.
Bangsi D; Zhou J; Sun Y; Patel NP; Darga LL; Heilbrun LK; Powell IJ; Severson RK; Everson RB
Urol Oncol; 2006; 24(1):21-7. PubMed ID: 16414488
[TBL] [Abstract][Full Text] [Related]
7. Ethnic differences in the frequency of prostate cancer susceptibility alleles at SRD5A2 and CYP3A4.
Zeigler-Johnson CM; Walker AH; Mancke B; Spangler E; Jalloh M; McBride S; Deitz A; Malkowicz SB; Ofori-Adjei D; Gueye SM; Rebbeck TR
Hum Hered; 2002; 54(1):13-21. PubMed ID: 12446983
[TBL] [Abstract][Full Text] [Related]
8. Polymorphisms in CYP17 and CYP3A4 and prostate cancer in men of African descent.
Taioli E; Sears V; Watson A; Flores-Obando RE; Jackson MD; Ukoli FA; de Syllos Cólus IM; Fernandez P; McFarlane-Anderson N; Ostrander EA; Rodrigues IS; Stanford JL; Taylor JA; Tulloch-Reid M; Ragin CC
Prostate; 2013 May; 73(6):668-76. PubMed ID: 23129512
[TBL] [Abstract][Full Text] [Related]
9. Characterization of CYP1A2, CYP2C19, CYP3A4 and CYP3A5 polymorphisms in South Brazilians.
Kohlrausch FB; Carracedo Á; Hutz MH
Mol Biol Rep; 2014 Mar; 41(3):1453-60. PubMed ID: 24443221
[TBL] [Abstract][Full Text] [Related]
10. Androgen Metabolism Gene Polymorphisms, Associations with Prostate Cancer Risk and Pathological Characteristics: A Comparative Analysis between South African and Senegalese Men.
Fernandez P; Zeigler-Johnson CM; Spangler E; van der Merwe A; Jalloh M; Gueye SM; Rebbeck TR
Prostate Cancer; 2012; 2012():798634. PubMed ID: 23091730
[TBL] [Abstract][Full Text] [Related]
11. COX-2 promoter polymorphisms and the association with prostate cancer risk in South African men.
Fernandez P; de Beer PM; van der Merwe L; Heyns CF
Carcinogenesis; 2008 Dec; 29(12):2347-50. PubMed ID: 18974063
[TBL] [Abstract][Full Text] [Related]
12. CYP3A5 polymorphisms and their effects on tacrolimus exposure in an ethnically diverse South African renal transplant population.
Muller WK; Dandara C; Manning K; Mhandire D; Ensor J; Barday Z; Freercks R
S Afr Med J; 2020 Jan; 110(2):159-166. PubMed ID: 32657689
[TBL] [Abstract][Full Text] [Related]
13. Ethnical disparities of prostate cancer predisposition: genetic polymorphisms in androgen-related genes.
Li J; Mercer E; Gou X; Lu YJ
Am J Cancer Res; 2013; 3(2):127-51. PubMed ID: 23593537
[TBL] [Abstract][Full Text] [Related]
14. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I.
Staatz CE; Goodman LK; Tett SE
Clin Pharmacokinet; 2010 Mar; 49(3):141-75. PubMed ID: 20170205
[TBL] [Abstract][Full Text] [Related]
15. CYP3A4 genetic variant and disease-free survival among white and black men after radical prostatectomy.
Powell IJ; Zhou J; Sun Y; Sakr WA; Patel NP; Heilbrun LK; Everson RB
J Urol; 2004 Nov; 172(5 Pt 1):1848-52. PubMed ID: 15540736
[TBL] [Abstract][Full Text] [Related]
16. Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women.
Floyd MD; Gervasini G; Masica AL; Mayo G; George AL; Bhat K; Kim RB; Wilkinson GR
Pharmacogenetics; 2003 Oct; 13(10):595-606. PubMed ID: 14515058
[TBL] [Abstract][Full Text] [Related]
17. Genetic signature consistent with selection against the CYP3A4*1B allele in non-African populations.
Schirmer M; Toliat MR; Haberl M; Suk A; Kamdem LK; Klein K; Brockmöller J; Nürnberg P; Zanger UM; Wojnowski L
Pharmacogenet Genomics; 2006 Jan; 16(1):59-71. PubMed ID: 16344723
[TBL] [Abstract][Full Text] [Related]
18. Association between a CYP3A4 genetic variant and clinical presentation in African-American prostate cancer patients.
Paris PL; Kupelian PA; Hall JM; Williams TL; Levin H; Klein EA; Casey G; Witte JS
Cancer Epidemiol Biomarkers Prev; 1999 Oct; 8(10):901-5. PubMed ID: 10548319
[TBL] [Abstract][Full Text] [Related]
19. CYP3A4 and CYP3A5 genotyping by Pyrosequencing.
Garsa AA; McLeod HL; Marsh S
BMC Med Genet; 2005 May; 6():19. PubMed ID: 15882469
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive evaluation of the association between prostate cancer and genotypes/haplotypes in CYP17A1, CYP3A4, and SRD5A2.
Loukola A; Chadha M; Penn SG; Rank D; Conti DV; Thompson D; Cicek M; Love B; Bivolarevic V; Yang Q; Jiang Y; Hanzel DK; Dains K; Paris PL; Casey G; Witte JS
Eur J Hum Genet; 2004 Apr; 12(4):321-32. PubMed ID: 14560315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
